1. Adding Molecular Data to Prognostic Models can Improve their Predictive Power in Treated Patients with Myelodysplastic Syndromes (MDS). (April 2017) Authors: Nazha, A.; Al-Issa, K.; Zarzour, A.; Radivoyevitch, T.; Hamilton, B.; Gerds, A.; Mukherjee, S.; Adema, V.; Clemente, M.; Patel, B.; Hirsch, C.; Advani, A.; Bartlomiej, P.; Carraway, H.; Maciejewski, J.; Sekeres, M. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S33 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1050: THROMBOCYTOPENIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR IN A PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) [MOMENTUM]. (23rd June 2022) Authors: Vannucchi, A.; Mesa, R.; Gerds, A.; Al-Ali, H. K.; Lavie, D.; Kuykendall, A.; Grosicki, S.; Iurlo, A.; Goh, Y. T.; Lazaroiu, M.; Egyed, M.; Fox, M. L.; McLornan, D.; Perkins, A.; Yoon, S.-S.; Gupta, V.; Kiladjian, J.-J.; Donahue, R.; Kawashima, J.; Verstovsek, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 940 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P1051: A PHASE 2 STUDY OF IMG-7289 (BOMEDEMSTAT) IN PATIENTS WITH ADVANCED MYELOFIBROSIS. (23rd June 2022) Authors: Gill, H.; Yacoub, A.; Pettit, K.; Bradley, T.; Gerds, A.; Tatarczuch, M.; Shortt, J.; Curtin, N.; Rossetti, J.; Burbury, K.; Mead, A.; Göthert, J.; Koschmieder, S.; Jones, A.; Peppe, J.; Dias, J.; Natsoulis, G.; McClure, T.; Kleppe, M.; Hong, W.-J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 941 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P1063: EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A PHASE 2 STUDY. (23rd June 2022) Authors: Yacoub, A.; Borate, U.; Rampal, R.; Ali, H.; Wang, E.; Gerds, A.; Hobbs, G.; Kremyanskaya, M.; Winton, E.; O'Connell, C.; Goel, S.; Oh, S.; Schiller, G.; Assad, A.; Erickson-Viitanen, S.; Zhou, F.; Daver, N. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 953 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA. (23rd June 2022) Authors: Harrison, C.; Bose, P.; Mesa, R.; Gerds, A.; Oh, S.; Kiladjian, J.-J.; García-Gutierrez, V.; Vannucchi, A.; Scheid, C.; Sobas, M.; Verstovsek, S.; Buckley, S.; Roman-Torres, K.; Mascarenhas, J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 959 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. S195: MOMENTUM: PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) IN SYMPTOMATIC AND ANEMIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR. (23rd June 2022) Authors: Verstovsek, S.; Vannucchi, A.; Gerds, A.; Al-Ali, H. K.; Lavie, D.; Kuykendall, A.; Grosicki, S.; Iurlo, A.; Goh, Y. T.; Lazaroiu, M.; Egyed, M.; Fox, M. L.; McLornan, D.; Perkins, A.; Yoon, S.-S.; Gupta, V.; Kiladjian, J.-J.; Donahue, R.; Kawashima, J.; Mesa, R. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 96 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗